Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06065371 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2025 to Dec 2026
    • Study completion date: May 2026 to May 2027
    v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Nov 2024 to Nov 20, 2024
    v5
  3. Start date: Jun 2024 to Nov 2024
    • Primary completion date: Aug 2025 to Dec 2025
    • Study completion date: Feb 2026 to May 2026
    v4
  4. Start date: Feb 2024 to Jun 2024v3
  5. Start date: Oct 2023 to Feb 2024
    • Primary completion date: Apr 2025 to Aug 2025
    • Study completion date: Oct 2025 to Feb 2026
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Henry Ford Health System
91 trials monitored
See 3 trials at risk
Colorectal Cancer
3,394 trials monitored
See 159 trials at risk
Pancreatic Cancer
1,739 trials monitored
See 106 trials at risk
Gastric Cancer
1,278 trials monitored
See 63 trials at risk
and 1 more disease
This is a Phase I study to evaluate the safety and tolerability of sacituzumab govitecan in combination with capecitabine for advanced gastrointestinal cancers after progression on standard therapy, and to assess correlation of outcomes with the biomarker Trop-2.
Trial Details
NCT Number NCT06065371
Lead Sponsor Henry Ford Health System
Collaborators: Gilead Sciences
Conditions
(from sponsor)		 Gastrointestinal Cancer
Related terms Biliary Tract Neoplasms, Colorectal Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov